Free CME

  • FREE

    Wills Eye Knowledge Portal

    All CME at the Wills Eye Knowledge Portal is now free of charge. A good way to start is by taking the very helpful virtual video tour. Some recent titles are:
    • Pre-Operative Evaluation Anterior Segment Trauma
    • Keratoconus – Deep Anterior Lamellar Keratoplasty (DALK) for Keratoconus – Is It Worth It?
    • ECP for Glaucoma
    • Managing Diabetic Retinopathy in the Cataract Patient
    • Neovascular AMD Treatment Update

    Target Audience: Ophthalmologists

    See full details chevron_right
    • Cost: Free
    • Credit hours: 88
    • CME credits awarded by: Wills Eye Institute
    • Format: On-Demand Online, Video
    • Expiration of CME credit: 3 years after posting
  • FREE

    New Insights into Age-Related Macular Degeneration and Geographic Atrophy

    This activity consists of three sessions, each of which should take approximately 1 hour to complete.

    At the conclusion of New Insights into Age-Related Macular Degeneration and Geographic Atrophy, you will be able to:
    • Identify the risk factors for AMD and the role of the complement pathway in the pathogenesis of GA
    • Describe the progression of early AMD to GA and monitoring parameters that can identify disease progression
    • Discuss the importance of routine eye exams and prompt referral when patients with AMD experience disease progression
    • Assess the efficacy and safety of emerging treatment options for GA secondary to AMD
    • Identify patient barriers to the optimal management of AMD and how they may be effectively addressed through education
    • Describe the benefits of comprehensive, multidisciplinary approach to the management of AMD

    Target Audience:
    This program is intended for optometrists who have significant numbers of people with age-related macular degeneration and geographic atrophy in their patient care panels and other eye care professionals with an interest in the treatment of age-related macular degeneration and geographic atrophy.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 3
    • CME credits awarded by: New England College of Optometry
    • Format: On-Demand Online, Online Video
    • Material last updated: May 18, 2017
    • Expiration of CME credit: July 12, 2018
  • FREE

    Preserving Visual Function in the Aging Population

    Preserving Visual Function in the Aging Population consists of two lectures with discussion:
    • Preserving Visual Function in the Aging Population
    • ‘I Didn’t See This Coming!’ Optometric Case Studies in Visual Acuity Challenges

    The presenters are Mark T. Dunbar, OD, FAAO and Dean Elliott, MD.

    Target Audience:
    This program is intended for US-based optometrists who have significant numbers of older patients with decreased visual acuity in their patient care panels.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: New England College of Optometry
    • Format: On-Demand Online, Online Video
    • Material last updated: August 10, 2017
    • Expiration of CME credit: August 10, 2018
  • FREE

    Chronic Idiopathic Constipation (CIC): Optimizing Pharmacotherapeutic Management Strategies

    Chronic Idiopathic Constipation (CIC) discusses conventional therapies: bulking agents, softeners, stimulants, osmotics; recent additions and investigational agents: prucalopride, plecanatide, linaclotide, lubiprostone; non-pharmacologic therapies and their place relative to pharmacotherapy: dietary, mechanical, behavioral, and surgical interventions; biofeedback; and clinical pearls and difficult-to-treat cases.

    After reviewing Chronic Idiopathic Constipation (CIC), you will be able to:
    • Describe the pathophysiology of chronic idiopathic constipation
    • Describe the benefits and risks of pharmacotherapy for chronic idiopathic constipation and take them into account when formulating a treatment plan for different patients
    • Formulate an evidence-based treatment plan for a variety of patients with chronic idiopathic constipation.
    • Recommend therapy changes in patients with chronic idiopathic constipation who do not respond to a previously prescribed treatment

    Target Audience:
    Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in gastroenterology; and any other healthcare professionals with an interest in or who clinically encounter patients with chronic idiopathic constipation.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online, Online Video
    • Material last updated: October 02, 2017
    • Expiration of CME credit: October 02, 2019
  • FREE

    Fact or Fiction? Test Your Knowledge on Residual and Treatment-Emergent Symptoms in Major Depressive Disorder

    Although major depressive disorder (MDD) has a profound impact on individuals, families, and society, it remains undertreated. There are currently more than 4 million US adults who are inadequately treated for MDD. Numerous studies show that antidepressant therapies are superior to placebo, but most adults with MDD do not achieve an adequate response with first-line pharmacotherapy. Inadequate response to antidepressant therapy is associated with greater medical morbidity, more hospitalizations, decreased productivity, and more suicide attempts. Treatment of MDD should strive for return to premorbid status and full functional and cognitive recovery. However, survey data show that health care providers may lack confidence in the management of patients who have an inadequate response to an antidepressant. The major barriers to achieving full recovery are the continuation of residual symptoms and treatment-emergent symptoms associated with antidepressants. Even in those responding to antidepressants, residual and treatment-emergent symptoms such as weight gain, sleep disturbance, and sexual dysfunction can impede adherence and recovery. Additionally, poor cognitive functioning is an obstacle to remission. Although tools are available for the evaluation and monitoring of cognitive function in patients with MDD, they remain underutilized. In this enduring activity, expert faculty will provide opportunities to enhance knowledge and competence in the ability to differentiate residual and treatment-emergent symptoms and better assess and manage symptoms using evidence-based strategies to optimize available therapies.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Medical Education Resources
    • Format: On-Demand Online
  • FREE

    One Size Does Not Fit All: Optimizing Use of Major Depressive Disorder Specifiers to Improve Outcomes

    Major depressive disorder (MDD) is a highly heterogeneous disorder that is increasingly seen as a continuum, with emphasis on overlapping and subthreshold symptoms. To address this issue, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) included the use of specifiers, such as mixed features and anxious distress, with the diagnosis of MDD. Although DSM-5 specifiers improve utility and precision in the diagnosis of MDD and related disorders, they may not be widely adopted because some clinicians maintain a categorical approach toward depression. The risk when clinicians avoid specifiers is significant because patients with diverse depressive illnesses should be diagnosed, monitored, and treated differently. Further, compared with MDD alone, the presence of mixed features or anxious distress in patients with MDD may be associated with diminished response to antidepressants, more severe symptoms, increased hospitalization, greater risk for suicide, and other deleterious outcomes. It is important for health care providers to appreciate the importance of MDD specifiers, their diagnostic criteria, and implications for evidence-based treatment. This activity was created to enhance knowledge and competence of health care providers who evaluate and manage patients with depression and clinical features of hypomania, mania, or anxiety.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: Medical Education Resources
    • Format: On demand online
  • FREE

    Pilot for Pulmonary COPD Expert Interviews

    Pilot for Pilot for Pulmonary COPD Expert Interviews reviews topics including:
    • What is the 2017 GOLD standard for managing patients with COPD?
    • Stepping up or stepping down – which direction for COPD patients?
    • Is the delivery system a good match for your patients with COPD?

    After completing the Pilot for Pilot for Pulmonary COPD Expert Interviews, you should be better able to:
    • Examine the data and expert recommendations concerning the use of ICS in patients with COPD
    • Evaluate data on the use of single and combination bronchodilators in patents with COPD
    • Discuss clinical scenarios where ICS should or should not be considered

    Target Audiences:
    Pulmonologists, critical care clinicians and other healthcare professionals involved in the management of patients with COPD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: The France Foundation
    • Format: On-Demand Online
    • Material last updated: May 31, 2017
    • Expiration of CME credit: May 31, 2018
  • FREE

    Hormone Receptor-Positive Advanced/Metastatic Breast Cancer: A Deeper Look into CDK4/6 Inhibitors

    Hormone Receptor-Positive Advanced/Metastatic Breast Cancer: A Deeper Look into CDK4/6 Inhibitors consists of a single lecture, with discussion, by Richard S. Finn, MD.

    After viewing Hormone Receptor-Positive Advanced/Metastatic Breast Cancer, you will be better able to:
    • Address the current advances and challenges of treating HR+, HER2- advanced and metastatic breast cancer
    • Evaluate new safety and efficacy data of CDK4/6 inhibitors for HR+, HER2- advanced and metastatic breast cancer
    • Anticipate and plan effective strategies to manage CDK4/6 inhibitor treatment-related side effects

    Target Audience:
    This program is intended for medical, radiation and surgery oncologists, breast surgeons, oncology nurse practitioners, pharmacists, and other health care professionals who treat patients with breast cancer.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Albert Einstein College of Medicine
    • Format: On-Demand Online, Online Video
    • Material last updated: June 28, 2017
    • Expiration of CME credit: December 28, 2017
  • FREE

    Pharmacotherapy for Hepatocellular Carcinoma (HCC): Therapeutic Updates, Best Practices, and Emerging Therapies

    Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related deaths and one of the more common types of cancer affecting the population worldwide.

    After completing Pharmacotherapy for Hepatocellular Carcinoma (HCC): Therapeutic Updates, Best Practices, and Emerging Therapies physicians will better be able to:

    • Apply existing guideline recommendations in the diagnosis of HCC
      Identify present and emerging pharmacotherapeutic treatments for management of unresectable HCC and apply them to patient cases using evidence-based medicine.
    • Describe how to manage challenges that arise during treatment with present and emerging pharmacotherapeutic treatments for HCC, including adverse effect management, and apply that knowledge to a patient case
    • Describe the challenges associated with treating patients with HCC, focusing specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat the disease, and apply that information in optimizing patient care in a patient case

    Target Audience: medical oncologists, hepatologists, interventional radiologists, endocrinologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with HCC, and. patients and/or their caregivers may also derive benefit from participating in the learning activity.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: February 19, 2019
    • Expiration of CME credit: February 19, 2021
  • FREE

    An Update on Fixed-Dose LAMA/LABA Inhalers in COPD

    An Update on Fixed-Dose LAMA/LABA Inhalers in COPD consists of written presentations by 4 experts on the use of Fixed-Dose Inhalers in COPD.

    Upon completion of An Update on Fixed-Dose LAMA/LABA Inhalers in COPD, you should be able to:
    • Evaluate key efficacy data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
    • Evaluate key safety data from clinical trials on new and emerging fixed-dose LAMA/LABA inhalers in COPD.
    • Apply information on the efficacy and safety of new/emerging LAMA/LABA inhalers in COPD to specific clinical scenarios.

    Target Audiences:
    This program is intended for health care professionals who treat and manage patients with COPD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: The France Foundation
    • Format: On-Demand Online
    • Material last updated: September 30, 2016
    • Expiration of CME credit: September 29, 2017